Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.61 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038352 | 0.84 | FLT3 (0.80) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4043027 | 0.84 | FLT3 (0.61) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4042878 | 0.83 | FLT3 (0.65) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4040965 | 0.83 | FLT3 (0.61) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL12779915 | 0.82 | FLT3 (0.59) | FLT3AXLPDGFRBAURKAKIT | |
| SCHEMBL4036384 | 0.82 | FLT3 (0.60) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4040972 | 0.81 | FLT3 (0.57) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4039131 | 0.78 | FLT3 (0.64) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4043508 | 0.77 | FLT3 (0.61) | FLT3AXLPDGFRBAURKAKIT | |
| SCHEMBL4038611 | 0.77 | FLT3 (0.62) | FLT3AXLAURKAKITIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7560266-B2 | Method to enhance biodegradation of sulfonated aliphatic-aromatic co-polyesters by addition of a microbial consortium | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| WO-2006084261-A2 | METHOD TO ENHANCE BIODEGRADATION OF SULFONATED ALIPHATIC-AROMATIC CO-POLYESTERS BY ADDITION OF A MICROBIAL CONSORTIUM | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060177930-A1 | Method to enhance biodegradation of sulfonated aliphatic-aromatic co-polyesters by addition of a microbial consortium | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-08-10 | — | — | US | disclosed |
| US-7053130-B2 | Method to accelerate biodegradation of aliphatic-aromatic co-polyesters by enzymatic treatment | E. I . DU PONT DE NEMOURS AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| WO-2005118693-A1 | METHOD TO ACCELERATE BIODEGRADATION OF ALIPHATIC-AROMATIC CO-POLYESTERS BY ENZYMATIC TREATMENT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050261465-A1 | Method to accelerate biodegradation of aliphatic-aromatic co-polyesters by enzymatic treatment | E.I. DU PONT DE NEMOURS AND COMPANY | 2005-11-24 | — | — | US | disclosed |
| US-6255451-B1 | DEGRADING POLYESTER, POLYESTERURETHANE, POLYCARBONATEESTER, POLYAMIDEESTER MOLDINGS, SHEET-LIKE PRODUCTS, COATINGS, ADHESIVES OR FOAMS WITH SOLUTIONS OF LIPASE FROM CANDIDA ANTARCTICA AND CUTINASE FROM HUMICOLA INSOLENS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | FLT3 220/4885AXL 762/4885TBXAS1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.